Open AccessPredicting binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase using molecular docking
Author(s) -
Nguyen Truong Tien,
Bui Tho Thanh
Publication year - 2019
Publication title -
khoa học và công nghệ: tự nhiên
Language(s) - English
Resource type - Journals
ISSN - 2588-106X
DOI - 10.32508/stdjns.v2i1.674
Subject(s) - adme , reverse transcriptase , docking (animal) , autodock , nucleoside reverse transcriptase inhibitor , chemistry , binding affinities , human immunodeficiency virus (hiv) , drug , nevirapine , pharmacokinetics , enzyme , physiologically based pharmacokinetic modelling , pharmacology , stereochemistry , in silico , virology , biology , biochemistry , antiretroviral therapy , rna , medicine , receptor , gene , viral load , nursing
The HIV/AIDS epidemic has become one of the most dangerous causes leading to millions of deaths around the world a year. To date, there have not had effective anti-HIV drugs in the treatment of HIV/AIDS because of emerging drug-resistant HIV mutants. In this work, potential non-nucleoside reverse transcriptase inhibitors (NNRTIs) were studied by means of molecular docking. The Diversity “drug-like” database from the National Cancer Institute, is composed of 1.420 compounds, was performed docking into the NNRTI binding pocket of HIV-1 reverse transcriptase crystal structure (1fk9) by using Autodock version 4.2.6. Pharmacokinetic properties (absorption, distribution, metabolism and excretion (ADME)) and toxicity of potential inhibitors within the body were predicted by the PreADMET version 2.0. The obtained results point out that the compound, coded 2518, was discovered as a potential inhibitor that has good human intestinal absorption, weakly bound to plasma proteins as well as is negative to mutagenicity and carcinogenicity. This rational inhibitor would be further studied in order to contribute informations finding new anti-HIV drugs.